Antibe Therapeutics Inc represents a strong commitment to innovation, scientific advancement, and patient well-being. As a pharmaceutical company, Antibe is focused on developing safer, non-addictive pain medications to address the significant global issue of opioid abuse. The company's corporate philosophy centers around utilizing their proprietary drug platform, hydrogen sulfide-releasing NSAIDs, to deliver groundbreaking solutions for pain management. With a team of dedicated professionals, Antibe Therapeutics Inc strives to improve patients' quality of life through their novel approach to pain relief. Through extensive research and clinical trials, the company aims to revolutionize pain management and provide safer alternatives for patients worldwide.

Antibe Therapeutics Inc primarily operates in Canada, where it is headquartered in Toronto, Ontario. Antibe Therapeutics Inc focuses on the development of pharmaceutical drugs to address inflammation and pain management. As a Canadian-based company, its primary presence is in the domestic market, serving the healthcare and pharmaceutical industry in Canada.

Antibe Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase 2B trials for its lead drug, ATB-346, demonstrating its safety, efficacy, and superior gastrointestinal safety profile compared to traditional nonsteroidal anti-inflammatory drugs. Antibe Therapeutics also received positive feedback from the US Food and Drug Administration (FDA) for its unique hydrogen sulfide-releasing technology, which has the potential to revolutionize pain and inflammation management. Furthermore, the company expanded its patent portfolio and secured key partnerships and collaborations with renowned organizations, enhancing its position in the pharmaceutical industry. Overall, Antibe Therapeutics has made remarkable strides in drug development, positioning itself as a promising player in the market.

Antibe Therapeutics Inc is a leading biotechnology company specializing in developing innovative pharmaceuticals targeted at inflammatory diseases and pain management. Founded in 2009, the company is focused on the development and commercialization of its proprietary drug platform, called Hydrogen Sulfide-Releasing Anti-Inflammatory Drugs (HSADs). Antibe Therapeutics Inc's mission is to address the limitations of current anti-inflammatory and pain medications by developing safer and more effective alternatives. With a strong team of experienced researchers and scientists, the company has made significant progress in advancing its drug candidates through preclinical and clinical trials. As a forward-thinking biotech firm, Antibe Therapeutics Inc continually strives to create value for its stakeholders and improve patients' lives through groundbreaking pharmaceutical innovations.

The main competitors of Antibe Therapeutics Inc in the market include Acorda Therapeutics, Inc., Amgen Inc., and BioMarin Pharmaceutical Inc. These companies are also engaged in the development and commercialization of innovative therapeutics in various therapeutic areas.

Antibe Therapeutics Inc is primarily active in the pharmaceutical industry.

Antibe Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for pain and inflammation. The company's business model revolves around developing safer, more effective drugs that target areas of high unmet medical need. Antibe Therapeutics utilizes its proprietary drug platform, known as "ATB-346," to create non-addictive, anti-inflammatory therapeutics that minimize the gastrointestinal side effects associated with traditional nonsteroidal anti-inflammatory drugs (NSAIDs). By improving the safety and tolerability profile of these drugs, Antibe Therapeutics aims to provide better treatment options for patients suffering from pain and inflammation-related conditions.

Antibe Therapeutics P/E suhe on −0,68.

Antibe Therapeutics KUV on 0.

AlleAktien kvaliteediskoor ettevõttele Antibe Therapeutics on 4/10.

Praegu ei saa Antibe Therapeutics käivet arvutada.

oodatud Antibe Therapeutics kasum on −22,60 mln. CAD.

Antibe Therapeutics Inc. is a biopharmaceutical company focused on developing pain medications. They use patented technology to provide a safe and effective alternative to conventional nonsteroidal anti-inflammatory drugs (NSAIDs). They conduct clinical studies to assess the efficacy and safety of their products and have several candidates in different stages of development. Their main product, ATB-346, is a hybrid molecule that reduces the side effects of aspirin. It has shown strong analgesic effects without the gastrointestinal and cardiovascular risks of aspirin. They also have other product candidates in their pipeline, including ATB-352 and ATB-340. Antibe Therapeutics generates revenue by licensing their technology and products to other companies, and they have partnerships with pharmaceutical companies to accelerate development and distribution. They have a variety of distribution channels, including direct sales, retail partnerships, and online platforms. The company has a strong financial strategy, having completed funding rounds and received government grants. Overall, Antibe Therapeutics is developing innovative pain medications with a proprietary technology, and they are well-positioned to meet the needs of pain patients.

Antibe Therapeutics maksab dividendi 0 CAD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Antibe Therapeutics jaoks arvutada või ettevõte ei maksa dividende välja.

Antibe Therapeutics ISIN on CA0370255097.

Antibe Therapeutics WKN on A2QJPN.

Antibe Therapeutics tähis on ATE.TO.

Viimase 12 kuu jooksul maksis Antibe Therapeutics dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Antibe Therapeutics tõenäoliselt dividendi summas 0 CAD.

Antibe Therapeutics praegune dividenditootlus on .

Antibe Therapeutics maksab kvartaalset dividendi. See makstakse välja kuudel .

Antibe Therapeutics maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 CAD. See vastab dividenditootlusele 0 %.

Antibe Therapeutics on liigitatud sektorisse 'Tervis'.

Viimase Antibe Therapeutics dividendide saamiseks 3.12.2024 suuruses 0 CAD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 3.12.2024.

Viimane dividendimakse toimus 3.12.2024.

Aastal 2023 maksis Antibe Therapeutics 0 CAD dividende.

Antibe Therapeutics dividendid makstakse välja CAD.